KRYSTAL-4
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- NCT06875310 ↗
- Recruiting
- Mirati Therapeutics Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on KRYSTAL-4 (adagrasib plus pembrolizumab in untreated KRAS G12C non-squamous non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KRYSTAL-4 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin
- Arms
- Adagrasib · Experimental
- Placebo · Placebo comparator
- Enrollment
- 630 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Mirati Therapeutics Inc.
- Start
- Apr 24, 2025
- Primary completion
- Sep 7, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06875310 · updated Oct 27, 2026